REGN
Regeneron Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$827.72
−1.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 15.5B | 14.3B | 14.2B | 13.1B | 12.2B |
| Cost of Revenue | 2.4B | 2.1B | 2.0B | 2.2B | 1.7B |
| Gross Profit | 13.2B | 12.2B | 12.2B | 10.9B | 10.5B |
| Operating Expenses | |||||
| R&D Expense | 6.5B | 5.9B | 5.2B | 4.0B | 3.1B |
| SG&A Expense | 2.7B | 2.7B | 3.0B | 2.5B | 2.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 8.7M | 114.1M | 53.4M | (2.1M) | (89.9M) |
| Total Operating Expenses | 9.2B | 8.7B | 8.2B | 6.5B | 5.1B |
| Cost and Expenses | 11.6B | 10.8B | 10.2B | 8.8B | 6.8B |
| Operating Income (EBIT) | 4.0B | 3.6B | 4.0B | 4.3B | 5.4B |
| Non-Operating | |||||
| Interest Income | 735.2M | 716.8M | 711.4M | 495.9M | 160.1M |
| Interest Expense | 55.4M | 43.8M | 55.2M | 73.0M | 59.4M |
| Net Interest Income | 679.8M | 673.0M | 656.2M | 422.9M | 100.7M |
| Other Non-Op Income/Expense | 1.2B | 1.7B | 789.2M | (149.3M) | (526.8M) |
| Non-Operating Income (excl Interest) | (1.3B) | (1.7B) | (844.4M) | 76.3M | 467.4M |
| EBT (Pre-Tax Income) | 5.2B | 5.2B | 4.8B | 4.2B | 4.9B |
| Income Tax Expense | 837.3M | 725.8M | 367.3M | 245.7M | 520.4M |
| Bottom Line | |||||
| Net Income | 4.3B | 4.5B | 4.4B | 4.0B | 4.3B |
| Earnings from Cont. Ops | 4.3B | 4.5B | 4.4B | 4.0B | 4.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.3B | 4.5B | 4.4B | 4.0B | 4.3B |
| Per Share | |||||
| Basic EPS | $41.88 | $43.07 | $40.90 | $37.05 | $40.51 |
| Diluted EPS | $40.43 | $41.48 | $38.34 | $34.77 | $38.22 |
| Revenue Per Share | $150.24 | $137.12 | $131.62 | $122.94 | $113.66 |
| Shares | |||||
| Basic Shares Outstanding | 103.4M | 104.6M | 107.9M | 106.7M | 107.1M |
| Diluted Shares Outstanding | 106.8M | 108.6M | 115.1M | 113.7M | 113.5M |
| Profitability Metrics | |||||
| EBITDA | 5.8B | 5.8B | 5.3B | 4.7B | 5.3B |
| D&A | 528.6M | 543.7M | 482.9M | 421.0M | 341.4M |
| EBIT | 5.2B | 5.3B | 4.8B | 4.3B | 4.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026